DE69828287T2 - Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen - Google Patents

Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen Download PDF

Info

Publication number
DE69828287T2
DE69828287T2 DE69828287T DE69828287T DE69828287T2 DE 69828287 T2 DE69828287 T2 DE 69828287T2 DE 69828287 T DE69828287 T DE 69828287T DE 69828287 T DE69828287 T DE 69828287T DE 69828287 T2 DE69828287 T2 DE 69828287T2
Authority
DE
Germany
Prior art keywords
peptide
solid phase
terminus
terminal
unprotected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69828287T
Other languages
German (de)
English (en)
Other versions
DE69828287D1 (de
Inventor
Lynne Canne
B. Stephen KENT
Reyna Simon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Gryphon Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gryphon Therapeutics Inc filed Critical Gryphon Therapeutics Inc
Application granted granted Critical
Publication of DE69828287D1 publication Critical patent/DE69828287D1/de
Publication of DE69828287T2 publication Critical patent/DE69828287T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
    • C07K1/086—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents containing sulfur
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/023—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution using racemisation inhibiting agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C07K1/026—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution by fragment condensation in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/047—Simultaneous synthesis of different peptide species; Peptide libraries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
DE69828287T 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen Expired - Fee Related DE69828287T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4955397P 1997-06-13 1997-06-13
US49553P 1997-06-13
PCT/US1998/012278 WO1998056807A1 (en) 1997-06-13 1998-06-12 Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution

Publications (2)

Publication Number Publication Date
DE69828287D1 DE69828287D1 (de) 2005-01-27
DE69828287T2 true DE69828287T2 (de) 2005-12-15

Family

ID=21960431

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69828287T Expired - Fee Related DE69828287T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische ligation von ungeschützten oder n-cystein-geschützten peptiden in wässrigen lösungen
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69837170T Expired - Fee Related DE69837170T2 (de) 1997-06-13 1998-06-12 Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen

Country Status (9)

Country Link
US (4) US6326468B1 (OSRAM)
EP (1) EP1001968B1 (OSRAM)
JP (1) JP2002505672A (OSRAM)
AT (2) ATE354584T1 (OSRAM)
AU (1) AU745094B2 (OSRAM)
CA (1) CA2292724A1 (OSRAM)
DE (2) DE69828287T2 (OSRAM)
ES (2) ES2282788T3 (OSRAM)
WO (1) WO1998056807A1 (OSRAM)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184344B1 (en) * 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
US6849428B1 (en) * 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
EP1001968B1 (en) * 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
WO1999011655A1 (en) * 1997-09-04 1999-03-11 Gryphon Sciences Modular protein libraries and methods of preparation
AUPP589598A0 (en) 1998-09-14 1998-10-08 University Of Queensland, The Novel peptides
US7001745B1 (en) * 1998-09-30 2006-02-21 New England Biolabs, Inc. Intein mediated peptide ligation
AU768118B2 (en) * 1999-03-11 2003-12-04 Gryphon Sciences Chemical synthesis and use of soluble membrane protein receptor domains
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU2001284853A1 (en) * 2000-08-11 2002-02-25 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
US20040014082A1 (en) * 2000-08-11 2004-01-22 Invitrogen Corporation Highly homogeneous molecular markers for electrophoresis
JP2004507557A (ja) * 2000-09-01 2004-03-11 グリフォン　セラピューティクス，インコーポレーテッド 求核物質に対して安定なチオエステル生成化合物、製造および使用の方法
CA2435394C (en) * 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
DE60216468T2 (de) * 2001-03-09 2007-09-27 Boston Probes, Inc., Bedford Kombinationsoligomere betreffende verfahren, kits und zusammensetzungen
GB0113657D0 (en) * 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
EP2042196B1 (en) 2001-10-10 2016-07-13 ratiopharm GmbH Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)
WO2003106615A2 (en) * 2002-06-10 2003-12-24 Geneprot, Inc. Post-cleavage sulfur deprotection for convergent protein synthesis by chemical ligation
AU2002328824A1 (en) * 2002-06-29 2004-01-19 Aquanova German Solubilisate Technologies (Agt) Gmbh Isoflavone concentrate and method for production thereof
US7166574B2 (en) * 2002-08-20 2007-01-23 Biosurface Engineering Technologies, Inc. Synthetic heparin-binding growth factor analogs
US7598224B2 (en) * 2002-08-20 2009-10-06 Biosurface Engineering Technologies, Inc. Dual chain synthetic heparin-binding growth factor analogs
US8227411B2 (en) 2002-08-20 2012-07-24 BioSurface Engineering Technologies, Incle FGF growth factor analogs
US7981862B2 (en) 2003-08-19 2011-07-19 Biosurface Engineering Technologies, Inc. Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis
AU2003300859A1 (en) * 2002-12-11 2004-06-30 New England Biolabs, Inc. Carrier-ligand fusions and uses thereof
WO2004061094A1 (en) 2002-12-30 2004-07-22 Gryphon Therapeutics, Inc. Water-soluble thioester and selenoester compounds and methods for making and using the same
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
ES2333598T5 (es) * 2003-05-06 2013-09-04 Biogen Idec Hemophilia Inc Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia.
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
WO2004105685A2 (en) * 2003-05-22 2004-12-09 Gryphon Therapeutics, Inc. Displaceable linker solid phase chemical ligation
US7414028B1 (en) 2004-02-04 2008-08-19 Biosurface Engineering Technologies, Inc. Growth factor analogs
US7528105B1 (en) 2004-02-10 2009-05-05 Biosurface Engineering Technologies Heterodimeric chain synthetic heparin-binding growth factor analogs
US20080227696A1 (en) 2005-02-22 2008-09-18 Biosurface Engineering Technologies, Inc. Single branch heparin-binding growth factor analogs
US7671012B2 (en) 2004-02-10 2010-03-02 Biosurface Engineering Technologies, Inc. Formulations and methods for delivery of growth factor analogs
US20060024347A1 (en) * 2004-02-10 2006-02-02 Biosurface Engineering Technologies, Inc. Bioactive peptide coatings
DE602005023714D1 (de) 2004-02-20 2010-11-04 Biosurface Eng Tech Inc Positiver modulator des knochenmorphogenetisches protein-2 (bmp-2)
UA88008C2 (en) 2004-04-09 2009-09-10 Чугей Сейяку Кабусики Кайся Water-soluble prodrugs
EP1749022A2 (en) * 2004-05-24 2007-02-07 Rigel Pharmaceuticals, Inc. Methods for cyclizing synthetic polymers
US7671023B2 (en) 2005-03-31 2010-03-02 Amylin Pharmaceuticals, Inc. Amylin agonist for treating depression, anxiety disorder and schizophrenia
TW200744603A (en) 2005-08-22 2007-12-16 Chugai Pharmaceutical Co Ltd Novel anticancer concomitant drug
US7674881B2 (en) * 2005-10-07 2010-03-09 The University Of Chicago Convergent synthesis of proteins by kinetically controlled ligation
KR20080066039A (ko) * 2005-10-19 2008-07-15 추가이 세이야쿠 가부시키가이샤 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제
US7820172B1 (en) 2006-06-01 2010-10-26 Biosurface Engineering Technologies, Inc. Laminin-derived multi-domain peptides
WO2008097536A2 (en) 2007-02-05 2008-08-14 Amylin Pharmaceuticals, Inc. Compositions and methods for treating psychiatric diseases and disorders
US8404804B2 (en) * 2007-08-28 2013-03-26 Ipsen Pharma S.A.S. Methods and intermediates for chemical synthesis of polypeptides and proteins
WO2011103409A1 (en) * 2010-02-18 2011-08-25 Advanced Proteome Therapeutics Inc. Site-specific modification of proteins through chemical modification enabling protein conjugates, protein dimer formation, and stapled peptides
EA201390450A1 (ru) 2010-09-28 2013-07-30 Амилин Фармасьютикалс, Ллк. Полипептиды с увеличенной продолжительностью действия
JP2014502252A (ja) 2010-09-28 2014-01-30 アミリン・ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー 作用持続時間が増した改変ポリペプチド
JP6006309B2 (ja) 2011-07-08 2016-10-12 アミリン・ファーマシューティカルズ, リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals, Llc 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
ES2732475T3 (es) 2011-07-08 2019-11-22 Aegerion Pharmaceuticals Inc Polipéptidos modificados por ingeniería genética que tienen una duración potenciada de la acción y una inmunogenicidad reducida
FR2981352B1 (fr) * 2011-10-17 2015-07-03 Centre Nat Rech Scient Procede de synthese de proteines
JP6290187B2 (ja) 2012-05-11 2018-03-07 クランツ，アレクサンダー 癌の処置のためのタンパク質の部位特異的標識及び標的送達
JP2015519344A (ja) 2012-05-21 2015-07-09 マサチューセッツ インスティテュート オブ テクノロジー 炭疽菌防御抗原ポアを通しての非天然化学実体のトランスロケーション
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
US11273176B2 (en) 2016-03-02 2022-03-15 The Brigham And Women's Hospital, Inc. Use of PLA2G5-deficient suppressive macrophages in suppression of inflammation
JP7067798B2 (ja) * 2017-03-02 2022-05-16 株式会社糖鎖工学研究所 アミノ酸ポリマーの製造方法
WO2020070587A1 (en) 2018-10-01 2020-04-09 Université De Genève Methods for producing a plurality of polypeptide variants suitable for biological analysis
WO2020110330A1 (ja) * 2018-11-30 2020-06-04 株式会社糖鎖工学研究所 ペプチドチオエステル、ペプチドの新規製造方法
AU2020361681A1 (en) 2019-10-10 2022-05-05 1859, Inc. Methods and systems for microfluidic screening
EP3838913A4 (en) * 2019-10-23 2021-11-03 MabPlex International Co., Ltd. OLIGOPEPTIDE LINKER INTERMEDIATE AND MANUFACTURING PROCESS FOR IT
WO2022266467A2 (en) 2021-06-17 2022-12-22 Dana-Farber Cancer Institute, Inc. Recombinant histone polypeptide and uses thereof
WO2024146707A1 (en) 2023-01-06 2024-07-11 Université De Genève Variant ligand conjugates for payload delivery

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064940A (en) * 1988-05-11 1991-11-12 Protein Technologies, Inc. Premixed dry reagent containing a protected amino acid and an activating agent for use in solid phase protein synthesis
US5101059A (en) * 1989-12-05 1992-03-31 Research Corporation Technologies, Inc. Amino acid protecting groups
PT832096E (pt) 1995-05-04 2002-01-30 Scripps Research Inst Sintese de proteinas atraves de ligacao quimica nativa
JP4358307B2 (ja) * 1996-12-24 2009-11-04 ザ スクリップス リサーチ インスティテュート 一般的化学結合
EP1001968B1 (en) * 1997-06-13 2004-12-22 Gryphon Therapeutics, Inc. Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
US6329468B1 (en) * 2000-01-21 2001-12-11 Bostik Findley, Inc. Hot melt adhesive based on semicrystalline flexible polyolefins

Also Published As

Publication number Publication date
DE69837170T2 (de) 2007-11-22
US20050209440A1 (en) 2005-09-22
ES2235336T3 (es) 2005-07-01
ES2282788T3 (es) 2007-10-16
EP1001968B1 (en) 2004-12-22
WO1998056807A1 (en) 1998-12-17
EP1001968A1 (en) 2000-05-24
DE69837170D1 (de) 2007-04-05
ATE285415T1 (de) 2005-01-15
JP2002505672A (ja) 2002-02-19
US7030217B2 (en) 2006-04-18
US20020132975A1 (en) 2002-09-19
US7094871B2 (en) 2006-08-22
ATE354584T1 (de) 2007-03-15
US6326468B1 (en) 2001-12-04
US20020169282A1 (en) 2002-11-14
AU8069598A (en) 1998-12-30
AU745094B2 (en) 2002-03-14
DE69828287D1 (de) 2005-01-27
CA2292724A1 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
DE69837170T2 (de) Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen
DE2540780C2 (OSRAM)
DE69430312T2 (de) Peralkylierte oligopeptidmischungen
Raibaut et al. Solid phase protein chemical synthesis
Bodanszky et al. Synthesis of secretin. I. The protected tetradecapeptide corresponding to sequence 14-27
DE60208684T2 (de) Verbesserte native chemische ligation mit drei oder mehreren komponenten
CA2273071C (en) Method for ligating oligopeptides
DD284031A5 (de) Verfahren zur herstellung eines kunstharzes
JPS6140680B2 (OSRAM)
JP2002525376A (ja) アミド結合形成のための補助基
BRPI0202783B1 (pt) processo para a síntese rápida de um peptídeo em solução em um solvente orgânico ou em uma mistura de solventes orgânicos, e, métodos para a síntese combinatória de coleções de peptídeo e para a síntese de peptídeo automatizada em solução
DE2923787A1 (de) Verfahren zur selektiven bildung von disulfidbruecken in polypeptiden und die dabei erhaltenen produkte als wirkstoffe enthaltende arzneimittel
DE69325987T2 (de) Verfahren zur Herstellung von Lachs-Calcitonin
DE69604759T2 (de) N alpha-2-(4-nitrophenylsulfonyl)ethoxycarbonyl-aminosäuren
DE60303314T2 (de) Verfahren zum carboxygruppenschutz der säuren c-terminalen aminosäuren bei chemischer verknüpfung von oligopeptiden
DE2830442C2 (OSRAM)
DE2505712A1 (de) Traegergebundene sowie biologisch aktive peptide und herstellungsverfahren dafuer
EP1518862B1 (en) Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution
Sucholeiki et al. An affinity chromatographic method for the purification of water-insoluble peptides
HU185238B (en) Process for preparing peptides containing guanidino-group
CH645880A5 (de) Synthetisches antigenaktives polypeptid, verfahren zu dessen herstellung und das polypeptid enthaltendes antigenes mittel sowie arzneimittel.
DE2703121A1 (de) Synthetische pentapeptide und sie enthaltende arzneimittel
EP4622989A1 (en) Method of preparing vasopressin
DE69102659T2 (de) Synthese von LH-RH-Analogen unter Anwendung eines zeitlich begrenzten minimalen Schutzes.
DE4404168A1 (de) Hirudinderivate und Verfahren zu deren Herstellung

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: AMYLIN PHARMACEUTICALS, INC. (N.D.GES.D. STAAT, US

8328 Change in the person/name/address of the agent

Representative=s name: DERZEIT KEIN VERTRETER BESTELLT

8339 Ceased/non-payment of the annual fee